Janssen, Genmab Hit with Patent Lawsuit Over Blood Cancer Drug

Wednesday, Apr 06, 2016

Johnson & Johnson unit Janssen Biotech Inc and Danish partner Genmab A/S have been hit with a patent lawsuit by German biotech firm MorphoSys AG over their blood cancer drug Darzalex.

The complaint, filed Monday in Delaware U.S. District Court, alleges that Darzalex, a antibody-based biologic drug approved to treat multiple myeloma, infringes a MorphoSys patent on the use of human antibodies.


Source :

Other News